A practical, high-throughout approach to the semi-quantitative measurement of SARS-CoV-2 neutralizing antibodies that is accessible to any test lab

Tuesday, September 28, 10:30 - 10:50 a.m.
Exhibit Hall, Theater 2
Supported by GenScript

Overview

The continued evolution of SARS-CoV-2 has presented a growing number of variants of concern that have begun to challenge the currently approved vaccines with new waves of presumed infection. However, the data are complicated by qPCR test results depicting variant viral particles in asymptomatic, fully vaccinated individuals who are likely immunologically protected from productive infection. It has been postulated that symptomatic individuals with the Delta variant can shed 1,000 times more viral particles than the wild type virus. This can potentially result in a comparably large number of viral particles entering the nasal buccal cavity of proximal vaccinated individuals who have presumed high immunity that could then be detected by qPCR. Although these “qPCR positive” but asymptotic, vaccinated, and immune individuals have detectable virus, it is postulated that immunity has rendered these particles inactive and neutralized. In the current testing paradigm, these individuals must unfortunately face quarantine even though the virus itself cannot enter their cells and propagate to give a productive infection. A shift in test strategy is therefore proposed whereby the vaccine-elicited, functional, and protective neutralizing antibodies are specifically and periodically measured in the vaccinated population to ensure a strong and prolonged immune response. The short talk presents key data exhibiting how an elegant and simple ELISA-based test opens the door to this possibility.

Presenter

Sean Taylor, Ph.D., MBA
Field Application Scientist Manager, North America
GenScript USA
Piscataway, NJ USA